Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2022-04-07
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection
NCT02140450
A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
NCT00538304
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
NCT03293992
Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate
NCT06730516
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
NCT03844945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study we aim to assess changes in intraocular pressure (IOP) among glaucomatous patients on systemic antihypertensive and antihistaminic drugs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antihypertensive drugs group
Changes in IOP among patients on antihypertensive drugs
Antihypertensive Agents
Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
Antihistaminic drugs group
Changes in IOP among patients on antihistaminic drugs
Antihistaminics
Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
Antihypertensive and antihistaminic drugs group
Changes in IOP among patients on both antihypertensive and antihistaminic drugs
Antihypertensive Agents
Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
Antihistaminics
Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antihypertensive Agents
Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
Antihistaminics
Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cases with dense corneal opacity or iris trauma that may affects gonioscopy examination.
* cases with secondary glaucoma.
35 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Abdelshafy
Lecturer of Ophthalmology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Abdelshafy
Banhā, QA, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Rc 9-22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.